Elevated serum levels of CXCL12 were found to be associated with increased osteoclast formation and bone loss in myeloma patients, and that targeted disruption of the CXCL12/CXCR4 axis inhibited osteolysis in a murine model of myeloma-associated bone loss [59]. This evidence concerns the gene CXCL12 and plasma cell myeloma.